Skip to content Skip to footer

Ivermectine als Behandelprotocol voor Huisartsen

Ivermectine is het alternatief voor Vaccineren, hierdoor vervalt de tijdelijke vergunning voor de experimentele vaccinaties.

Laat de Huisartsen Ivermectine voorschrijven voor de indicatie: Covid-19. Formuleer dit onmiddelijk als behandelprotocol.


Ivermectine als Behandelprotocol voor Huisartsen

Covid-19 wordt succesvol bestreden en voorkomen met het middel Ivermectine, Aldus meerdere wetenschappelijke publicaties.(zie onderaan deze pagina).

Bureaucratie mag levensreddende behandelingen middels toepassing van het juiste medicijn niet in de weg staan.

Laat de Huisartsen Ivermectine voorschrijven voor de indicatie: Covid-19. Formuleer dit onmiddelijk als behandelprotocol.

Ivermectine is het alternatief voor Vaccineren, hierdoor vervalt de tijdelijke vergunning voor de experimentele vaccinaties.
Omdat Ivermectine preventieve werking heeft kan Nederland bevrijd worden van de mens- onterende en slopende "preventieve"maatregelen.

We kunnen samen Nederland bevrijden, maar dan moet je wel je stem laten horen.
Teken voor behandeling met Ivermectine.

Teken, deel, Doneer!

Gericht aan: SWAB, NHG, Minister VWS (H.deJonge), Tweede Kamer
Wij: Het Volk
Constateren: Dat de wetenschappelijke wereld voor Covid-19 een Preventief en Curatief middel heeft gevonden in het reeds jarenlang bekende, beproefde en volkomen veilige middel; Ivermectine.
En Verzoeken: Dat Ivermectine wordt erkent als alternatief op Vaccineren en; Dat dit Ivermectine per direct als behandelprotocol voor Covid-19 door alle huisartsen moet worden voorgeschreven.


710 handtekeningen
Laatste Handtekeningen
710 Ms. Marie Jose R. Noord Brabant dec 29, 2021
709 Mr. Eric V. Utrecht dec 23, 2021
708 Mr. lex w. Nederland dec 17, 2021
707 Ms. Ria B. Zuid-holland nov 21, 2021
706 Mr. André K. sep 24, 2021
705 Mr. Mark R. Zuid-Holland aug 06, 2021
704 Ms. annelies R. nederland jun 07, 2021

Deel deze petitie



Of help ons middels een donatie

Bedankt voor de betaling; de status is: betaald.


Peer-reviewed publicaties

Ahmed, S. et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases, 2020; December

Alam, M. T. et al. Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study. European Journal of Medical & Health Sciences, 2020; vol. 2 (6)

Alam, M.T. et al. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons, 2020; vol. 38: p.10-15

Al-Kuraishy, H. et al. Is ivermectin–Azithromycin combination the next step for COVID-19?. Biomed Biotechnol Res J, 2020; vol. 4: S1:101-3;year=2020;volume=4;issue=5;spage=101;epage=103;aulast=Al-Kuraishy

Azam, N. Some home remedies used for treatment of COVID-19 in Bangladesh. Journal of Medicinal Plant Studies. 2020; vol. 8(4): p.27-32

Bernigaud, C. et al. Bénéfice de l’ivermectine: de la gale à la COVID-19, un exemple de sérendipité. Annales de Dermatologie et de Vénéréologie, 2020; vol. 147 (12): A194

Caly, L. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 2020; vol. 178 (June)

Camprubi, D. et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE, 2020; vol. 15 (11)

Carvallo, H. Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. Journal of Biomedical Research and Clinical Investigation, 2020; vol. 2 (1)

Chacar, A. et al. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. Internation Journal of Sciences, 2020; vol. 9 (September): p.31-35

Espitia-Hernandez, G. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research: An International Journal of Medical Sciences, 2020; vol. 31 (5)

Fonseca, S. et al. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. Travel Medicine and Infectious Diseases, 2020; vol.38

Guerrero, E. et al. COVID-19: The Ivermectin African Enigma. Damage Control Surgery (I), 2020; vol. 51(4)

Guzzo, C. et al. Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. Journal of Clinical Pharmacology, 2002; vol. 42(10): p.1122-1133

Heidary, F. & R. Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics, 2020; vol. 73: p. 593-602

Hellwig, M. & A. Maya A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. International Journal of Antimicrobial Agents, 2020; November

Hussain, S. Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh. International Journal of Molecular and Immuno Oncology, 2020; December

Jans, D. & K. Wagstaff Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells, 2020; vol. 9(9)

Kahn, S. et al. Ivermectin for COVID-19: A broad-spectrum veterinary endectocide with antiviral activity. Journal of Food and Animal Sciences, 2020; vol. 1(1): p.1-6

Kaur, H. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological Reports, 2021

Kory, P. et al. Review of .the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Frontiers in Pharmocology, 2020

Lehrer, S. & P. Rheinstein Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo, 2020; vol. 34(5): p. 3023-3026

Li, N. et al. Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment. Journal of Cellular Physiology, 2020; p.1-17

Madrid, R. et al. Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation. Heliyon, 2021; vol. 7(1)

McCullough, P. et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine, 2020; vol 21 (4): p.517-530

Mittal, N & R. Mittal. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Medical Hypotheses, 2020; November

Momekov, G. & D. Momekova Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment, 2020; vol. 34 (1)

Mody, V. et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biology, 2021; 4: art. 93

Navarro, M. et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2020; vol. 75(4): p.827-834

Núñez, A. et al. Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19 Study conducted at the Social Security Institute for Workers of the State of Chiapas, ISSTECH, Mexico. International Journal of Innovative Science and Research Technology, 2020; vol. 5(7): p.211-215

Padhy, B. et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Journal of Pharmacy and Pharmaceutical Sciences, 2020; 23: p.462-469

Procter, B. et al. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 2020; vol. 21 (4): p. 611-614

Podder, C.S. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. I.M.C. Journal of Medical Science, 2020; vol. 14 (2)

Rajter, J. et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study. CHEST, 2020; october

Schmith, V. et al. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin. Pharmocol Ther., 2020; May

Shouman, W. Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A Randomised clinical trial. Journal of Clinical and Diagnostic Research, 2020

Spoorthi, V & Sasank S. Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2. IAIM, 2020; vol. 7(10): p.177-182.

Surnar, B. Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19. ACS Pharmalogical & Translational Science, 2020; December

Preprint studies

Afsar, N. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting

Aguirre-Chang, G. et al. Post-Acute or Prolonged COVID-19 Treatment with Ivermectin for Patients with Persistent, or Post-Acute Symptoms

Aguirre-Chang, G. & A. Figueredo, COVID-19: Pre-exposure Prophylaxis with Ivermectin for exposed people.

Aguirre-Chang, G. et al. COVID-19 Persistent: Treatment with Ivermectin and Acetylsalicylic acid of patients with the persistent syndrome of anosmia or hyposmia

Babalola, O. et al. Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos.

Behera, P. et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study.

Budhiraja, S. et al. Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience

Bukhari, K. et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease

Cadegiani, F. A. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

Carvallo, H. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19.

Chamie-Quintero, J. et al. Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments

Cobos-Campos, R. et al. Potential use of ivermectin for the treatment and profilaxis of SARS-CoV-2 infection: Efficacy of ivermectin for SARS-CoV-2

Dias de Melo, G. Anti-COVID-19 efficacy of ivermectin in the golden hamster

Elgazzer, A. et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

Frances-Monerris, A. et al. Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent

Gorial, F.I. et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Hashim, H.A. et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq

Hill, A. et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Jeffreys, L. et al. Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

Kalfas, S. et al. The Therapeutic Potential of Ivermectin for COVID-19: a systematic review of Mechanisms and Evididence.

Kirty, R. et al. Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial

Krolewiecki, A. et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial

Lawrie, T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance.

Mohan, A. et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial.

Morgenstern, J. et al. The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020

Niaee, M.S. et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

Soto-Becarra, P. et al. Real-world effectiveness  Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Studyof hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru

Swargiary, A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies.

Turkia, M. FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 – A Brief Review

Clinical Trials met resultaten

Chala, R. Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc). 2021

Mahmud, R, Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection. 2020

Okomuş, N. Ivermectin for servere COVID-19 management. 2020

Raad, H. In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial. 2020

Shouman, W. M.  Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19. 2020

Review article

Frediansyah, A. et al. Antivirals for COVID-19: A critical review. Clinical Epidemiology and Global Health, 2020; vol. 9: p. 90-98

Scientific Letters

Khan, S. et al. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Archivos de Bronconeumología, 2020; vol. 56 (12): p. 828-830

Pandey, S. et al. Ivermectin in COVID-19: What do we know? Diabetes & Metabolic Syndrome: Research & Reviews, 2020; vol. 14 (6): p. 1921-1922

Letter to the editor

Gupta, D. et al. Ivermectin: potential candidate for the treatment of Covid 19. The Brazilian Journal of Infectious Diseases, 2020; vol. 24 (4): p. 369 -371

DiNicolantonia, J. et al. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart, 2020; vol. 7(4)

Pena-Silva, R. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. British Journal of Clinical Pharmocology. 2020

Rizzo, E. Ivermectin, Antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg´s Archives of Pharmacology, 2020; July, 393 (7): p. 1153-1156.

Vora, A. et al. White paper on Ivermectin as a potential therapy for COVID-19. Indian Journal on Tuberculosis, 2020; vol. 67(3): p.448-451

ClaimedIn © 2023. Alle Rechten Voorbehouden

Disclaimer: Petities geven niet per definitie de mening van ClaimedIn weer